Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ CG 858

Click to view available options
Quantity:
5 mg
Description
CG 858 is a selective BRAF-V600E protein Degrader (uSMITETM). CG 858 comprises the BRAF kinase inhibitor vemurafenib linked to the E3 ligase ligand Thalidomide (Cat. No. 0652). CG 858 dose-dependently degrades BRAF-V600E but not wild type BRAF, and reduces cell viability and colony formation in HT-29 and A375 cells (DC50 values are 124 nM and 500 nM, respectively). Exhibits 88% degradation at 500 nM. CG 858 also impairs melanoma cell growth.
CG 858 negative control (Cat. No. 7428) also available.
Specifications
Specifications
Chemical Name or Material | N-[[4-[3-[2,6-Difluoro-3-[(propylsulfonyl)amino]benzoyl]-1 H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]methyl]-5-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1 H-isoindol-5-yl]amino]pentanamide |
CAS | 2417296-82-1 |
Quantity | 5 mg |
Target | Active Degraders |
Molecular Formula | C42H39F2N7O8S |
Purity | 0.98 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction